Reperfusion therapy for acute myocardial infarction: Drugs or devices? Is this the right question?

Clinical Cardiology

Volumn 27, Issue 5, 2004, Pages 254-256

  Pavlides, Gregory S ^a   Cokkinos, Dennis V ^a,b  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

^b NONE   (Greece)

Author keywords

Acute myocardial infarction; Fibrinolysis; Primary percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ALTEPLASE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STREPTOKINASE;

ACUTE HEART INFARCTION; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; CORONARY STENT; DRUG EFFICACY; EMBOLISM; FIBRINOLYTIC THERAPY; HALF DRUG DOSE; HEART MUSCLE REPERFUSION; HUMAN; LOW DRUG DOSE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; RESTENOSIS; REVIEW; ST SEGMENT ELEVATION;

EID: 2542539005     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960270502     Document Type: Review

References (21)

1. Lincoff AM, Topol EJ: Illusion of reperfusion: Does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation 1993;88:1361-1374
2. Antman EM, Giugliano CM, Gibson CM, McCabe CH, Coussement P, Kleiman NS, Vahanian A, Adgey AA, Menown I, Rupprecht HJ, Var Wieken R, Ducas J, Scherer J, Anderson K, Van de Werf F, Braunwald E: Abciximab facilitates the rate and extent of thrombolysis. Results of Thrombolysis in Myocardial Infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 1999;99:2720-2732
3. Topol EJ, The GUSTO V Investigators: Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial. Lancet 2001;357:1905-1914
4. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators: Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-613
5. PCAT Collaborators: Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: Six-month follow-up and analysis of individual patient data from randomized trials. Am Heart J 2003;145:47-57
6. Grines CL, Cox DA, Stone GW, Garcia E, Mattos LA, Giambartolon A, Brodie BR, Madonna O, Eijgelshoven M, Lansky AJ, O'Neill WW, Morice MC: Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent primary angioplasty in myocardial infarction study group. N Engl J Med 1999;341:1949-1956
7. Brener SJ, Barr LA, Burchenal JE Katz S, George BS, Jones AA, Cox ED, Gainey PC, White HJ, Cheek HB, Moses JW, Moliterno DJ, Effron MB, Topol EJ: Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and primary, PTCA organization and randomized trial (RAPPORT) investigators. Circulation 1998;98:734-741
8. Stone GW, Grines CL, Cox DA Garcia E, Tcheng JE, Friffin JJ, Guagliumi G, Stuckey T, Turco M, Caroll JD, Rutherford BD, Lans AJ: Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-966
9. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Vill P, Boulenc JM, Morice MC, Maillard L, Pansieri M, Choussat R, Pine P: ADMIRAL Investigators: Abciximab before direct angioplasty and stenting in myocardial infarction regarding acute and long-term follow-up. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903
10. Brodie BR, Stuckey TD, Hansen C, Muncy D: Benefit of coronary reperfusion before intervention on outcomes after primary angioplasty for acute myocardial infarction. Am J Cardiol 2000 Jan 1;85(1):13-18
11. Ross AM, Coyne KS, Reiner JS, Greenhouse SW, Fink C, Frey A, Moreyra E, Traboulsi M, Racine N, Riva AL, Thompson MA, Rohrb S, Lundergan CF: A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: The PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial. J Am Coll Cardiol 1999;34:1954-1962
12. Strategies for Patency Enhancement in the Emergency Department (SPEED) group: Trial of abxicimab with and without low-dose reteplase for acute myocardial infarction. Circulation 2000;101:2788-2794
13. The GRACE Investigators: Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: A multinational registry of patients hospitalized with acute coronary syndromes. Am Heart J 2001;141:190-199
14. Boersma E, Maas AC, Deckers JW, Simoons ML: Early thrombolytic treatment in acute myocardial infarction: Reappraisal of the golden hour. Lancet 1996;348:771-775
15. Berger PB, Ellis SG, Holmes DR Jr, Granger CB, Criger DA, Betriu E, Topol EJ, Califf RM: Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: Results from the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. Circulation 1999;100:14-20
16. Weaver WD, Cerqueira M, Hallstrom AP, Litwin PE, Martin JS, Kudenchuk PJ, Eisenberg M: Pre-hospital-initiated vs. hospital-initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. J Am Med Assoc 1993;270:1211-1216
17. Bonnefay E, Lapostolle F, Leizorovicz A, Steg G, McFaden EP, Dut PY, Cattan S, Boullenger E, Machecours J, Lacroute JM, Cassagnes E, Dissait F, Topuboul P: Comparison of angioplasty and prehospital thrombolysis in acute myocardial infarction study group. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: A randomized study. Lancet 2002;360:825-829
18. Andersen HR, Nielsen TT, Rasmussen K, Thuesen L, Kelbaek H, Thayssen P, Abiuldgaard U, Pedersen F, Madsen JK, Gande P, Villadsen AB, Krusell LR, Haghfelt T, Lomhott P, Husted SE, Vigholt E, Kjaergard HK, Mortensen LS for the DANAMI-2 Investigators: A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003;349:733-742
19. Aversano T, Aversano L, Passamani E, Knatterud G, Terrin M, Williams D, Forman S: Thrombolytic therapy vs. primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery. A randomized controlled trial. J Am Med Assoc 2002;287:1943-1951
20. Dibra A, Mehilli J, Dirschinger J, Pache J, Neverve J, Schwaiger M, Schömig A, Kastrati A: Thrombolysis in myocardial infarction. Myocardial perfusion grade in angiography correlates with myocardial salvage in patients with acute myocardial infarction treated with stenting or thrombolysis. J Am Coll Cardiol 2003;41:925-929
21. Bell RM, Yellon DM: Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J Am Coll Cardiol 2003;41:508-515